tocilizumab (RoActerma)

following an abbreviated submission

tocilizumab (RoActemra®)  is accepted for use within NHS Scotland.

Indication under review: tocilizumab in combination with methotrexate is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with methotrexate. Tocilizumab can be given as monotherapy in case of intolerance to methotrexate or where continued treatment with methotrexate is inappropriate.

Tocilizumab has previously been accepted by SMC for treatment of adult rheumatoid arthritis and in active systemic juvenile idiopathic arthritis in patients from 2 years of age who have responded inadequately to previous therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Tocilizumab can be given as monotherapy (in case of intolerance to methotrexate or where treatment with methotrexate is inappropriate) or in combination with methotrexate.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tocilizumab. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.